Roscovitine Is an Effective Inducer of Apoptosis of Ewing’s Sarcoma Family Tumor Cells In vitro and In vivo

Oscar M. Tirado, Silvia Mateo-Lozano, and Vicente Notario

Laboratory of Experimental Carcinogenesis, Department of Radiation Medicine, Georgetown University Medical Center, Washington, District of Columbia

Abstract

The Ewing’s sarcoma family of tumors (ESFT) comprises several well-characterized malignant neoplasms with particularly aggressive behavior. Despite recent progress in the use of multimodal therapeutic approaches and aggressive local control measures, a substantial proportion of patients die because of disease progression. Furthermore, this outcome has not changed significantly over the last 15 to 20 years. Consequently, new, more effective therapeutic options are sorely needed for the treatment of ESFT. Because ESFT cells overexpress several cyclin-dependent kinases (CDK), we explored the efficacy against ESFT of roscovitine, a CDK inhibitor shown to be surprisingly safe for humans in clinical trials of their anticancer activity. Results showed that ESFT cell lines are uniformly sensitive to roscovitine. In addition to exerting comparatively minor cell cycle effects, roscovitine treatment concomitantly caused the up-regulation of the expression of the proapoptotic protein BAX and the down-regulation of both survivin and XIAP, thus resulting in caspase-dependent apoptosis. Furthermore, in vivo experiments showed that s.c. growth of ESFT xenografts was also significantly slowed by i.p. injection of roscovitine. These results strongly suggest that roscovitine may be an effective therapeutic agent against ESFT and recommend its evaluation against ESFT in clinical trials and its inclusion in future treatment protocols. (Cancer Res 2005; 65(20): 9320-27)

Introduction

Ewing’s sarcoma family of tumors (ESFT), which includes Ewing’s sarcoma (EWS), Askin’s tumor, and primitive neuroectodermal tumors (PNET), are the second most common bone tumors in children, adolescents, and young adults (1). These tumors are characterized by the presence, in over 90% of the cases, of a balanced translocation between human chromosomes 11 and 22 that joins the 5’ end of the EWS gene and the 3’ end of the FLI1 gene. The resulting hybrid gene encodes the EWS/FLI1 fusion protein, which has been shown to be responsible for the malignant properties of ESFT (1). Despite aggressive combinations of chemotherapy, radiotherapy, and surgery, ~50% of patients eventually relapse, even after 5 years, and >30% of patients with localized disease and ~80% of patients with metastatic disease die due to disease progression (2). Although recently reported experimental evidence (3, 4) compellingly supports the introduction of promising, alternative therapeutic approaches for ESFT, new, more effective treatment options are sorely needed.

Molecular analyses have shown that, like most other human tumors (5, 6), ESFT frequently carry mutations in cell cycle regulators, including overexpression of cyclin D1 (7–10); elevated expression of cyclin-dependent kinase 2 (CDK2; ref. 11); losses or low expression of CDK inhibitors, such as p16^INK4A, p21^WAF1, or p27^KIP1 (12–14); and other chromosome 9 abnormalities (15, 16). Reversion of some of these alterations after forced down-regulation of EWS/FLI-1 strongly suggested that G1-S regulatory genes may work downstream of EWS/FLI-1 and that imbalances in their expression may contribute to tumorigenesis (1). Furthermore, an association has been detected between elevated expression of CDK2 and high risk/poor prognosis Ewing’s sarcoma (11). This finding is particularly important because CDK2 inhibition has become recently an attractive therapeutic approach (5, 17, 18). Indeed, inhibitors such as roscovitine (CYC202, Seliciclib, R-roscovitine) have been shown not only to inhibit the kinase activities of the CDK2/cyclin A and CDK2/cyclin E complexes with high specificity and potency (17, 18), but are also proving unexpectedly safe for humans in clinical trials of their anticancer activity (19–22). In addition, several lines of evidence showed that CDK inhibitory drugs induce apoptosis of tumor cells (5). Roscovitine has been reported to induce apoptosis of a variety of established tumor cell lines in culture and in tumor xenografts (19, 23–26). Because tumors with dysfunctional CDK inhibitors, a known characteristic of ESFT cells (12–14, 27, 28), have been reported to be especially susceptible to CDK inhibition (5, 29), it seemed extremely likely that ESFT cells may be highly sensitive to CDK inhibition. Consequently, we tested the effect of roscovitine on EWS and PNET cells in culture and in nude mice xenografts. Results of the present study show that roscovitine is indeed a very efficient inducer of apoptosis of ESFT cells, via a mechanism involving caspase activation and the up-regulation of Bax protein expression and has a potent antitumor activity. Therefore, our data strongly suggest that roscovitine may be a useful therapeutic agent for the treatment of ESFT.

Materials and Methods

Culture conditions, antibodies, and general reagents. A4573 and SK-ES-1 cells were obtained from Dr. Timothy J. Kinsella (University Hospitals of Cleveland, OH). TC-71 cells were obtained from Dr. Jeffrey A. Toretsky (Georgetown University Medical Center, Washington, DC). TC32, SK-N-MC, and SK-N-SH cells were obtained from American Type Culture Collection (Manassas, VA). SK-ES-1, A4573, and SK-N-MC cells were maintained in DMEM (Biosource, Camarillo, CA) supplemented with penicillin, streptomycin, and 10% fetal bovine serum (Life Technologies, Gaithersburg, MD). SK-N-SH, TC-32, and TC-71 cells were maintained in RPMI 1640 (Biosource) with the same supplements. Cells were maintained at 37°C.
in a humidified atmosphere of 5% CO₂ and 95% air. Polyclonal antibodies against Bax, cleaved caspase-3, cleaved caspase-9, and survivin were from Cell Signaling Technology (Beverly, MA). Monoclonal XIAP antibody was from BD PharMingen (Palo Alto, CA). β-Actin (Abcam, Ltd., Cambridge, United Kingdom) detection was used as loading reference. Oligonucleotide primers were purchased from Bio-Synthesis (Lewisville, TX). Roscovitine was purchased from EMD Biosciences, Inc. (San Diego, CA) or LC Laboratories (Woburn, MA). Trypan blue was obtained from Life Technologies (Grand Island, NY). All other general reagents were from Sigma-Aldrich (St. Louis, MO).

**Apoptosis and cell cycle assays.** Apoptosis was evaluated by viable cell counting and/or terminal deoxynucleotidyl transferase–mediated nick end labeling (TUNEL) assays. Cell viability was determined by the trypan blue exclusion method: Cells were suspended in 0.4% trypan blue in PBS, placed on a hemocytometer, and counted under the microscope. TUNEL assays were done for the in situ detection of apoptotic cells using the red-based TMR red-based TMR. In situ death Detection kit from Roche Diagnostics (Indianapolis, IN). Cells were cultured in chamber slides (Nunc, Naperville, IL) to a population density. Death Detection kit from Roche Diagnostics (Indianapolis, IN). Cells were plated at a density of 5 × 10⁵ cells. Sixteen hours after ros covitine exposure, cells were washed with PBS, fixed in freshly prepared paraformaldehyde (4% in PBS) for 30 minutes at room temperature, rinsed thrice in PBS, permeabilized with 0.2% Triton X-100 in PBS for 30 minutes, and incubated with the TUNEL reaction mixture for 1 hour at 37°C in a humidified atmosphere in the dark. TUNEL-positive cells were visualized with a Nikon E600 fluorescence microscope. For cell cycle analysis, cells were harvested 24 hours after exposure to ros covitine, washed once in PBS, fixed in citrate buffer (pH 7.6), resuspended in PBS containing 20 µg/mL of propidium iodide (Calbiochem-Novabiochem Corp., San Diego, CA), and incubated for 30 minutes at 37°C before flow cytometric analysis on a FACScan instrument (Becton Dickinson, San Jose, CA), done at the Flow Cytometry/Cell Sorting Shared Resource of the Vincent T. Lombardi Comprehensive Cancer Center. The same in situ death detection kit was used for TUNEL assays done on deparaffinized 5 µm tumor sections.

**Caspase assays.** Cultures of TC-71 and A4573 cells were established by plating either 2 × 10⁴ cells per well in 96-well tissue culture plates (for caspase activity determinations) or 2 × 10⁵ cells per well in six-well plates (for apoptosis assays). After overnight incubation, cells were treated for 24 hours with either 10⁻⁶mol/L ros covitine, 5 µg/mL cisplatin (as a positive inducer of caspase-3–dependent apoptosis), or DMSO vehicle (as the negative control), each in the presence or absence of the Ac-DEVD-CHO caspase-3 inducer of caspase-3–dependent apoptosis), or DMSO vehicle (as the negative control), each in the presence or absence of the Ac-DEVD-CHO caspase-3/7 inhibitor at a 20 µmol/L final concentration. All treatments were done in triplicate. Following treatment, the extent of apoptosis induction was determined as described above, and caspase-3/7 activity determinations were carried out using the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega, Madison, WI) following the manufacturer's protocol. Briefly, once the reagent and the cell culture plates had been equilibrated to room temperature, an equal volume of reagent was added directly to the cell cultures, the plates were shaken at 500 rpm, and the fluorescent output was measured 8 hours after adding the reagent in a fluorescence plate reader with a 485/535 excitation/emission filter and a gain setting of 25.

**Western blot analysis.** Cells were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors (1 mmol/L phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin, and 10 mg/mL leupeptin) and the lysates were centrifuged at 13,000 × g at 4°C for 30 minutes. Protein content in the supernatants was determined with the BCA protein assay system (Pierce, Rockford, IL). Proteins (40 µg) in cell extracts were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. After blocking with 5% nonfat dry milk in PBS containing 0.2% Tween 20, membranes were incubated at 4°C overnight with the different antibodies. Blots were then incubated for 1 hour at room temperature with horseradish peroxidase–conjugated secondary antibody (1:2,000) and the peroxidase activity was analyzed with the ECL chemiluminescence substrate system (Amersham Biosciences, Piscataway, NJ).

**Immunofluorescence.** Cells were grown in chamber slides, fixed, and permeabilized as described for TUNEL assays. Permeabilized cells were then incubated for 30 minutes at room temperature with 10% donkey serum in PBS to block nonspecific binding. After thorough rinsing with PBS, cells were incubated for 1 hour at 37°C with anti–cleaved caspase-3 antibody followed by 30 minutes at 37°C with FITC-coupled anti-rabbit antibody. Cells were rinsed again with PBS and twice with distilled water, and mounted in Vectashield medium for fluorescence with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA), which provided nuclear counterstaining and visualized using a Nikon E600 fluorescence microscope. Appropriate controls were maintained by substituting the primary antibody with normal donkey and/or rabbit serum to check for nonspecific binding.

**In vivo studies.** Male athymic nude mice (5-6 weeks old) were obtained from the National Cancer Institute. Mice were housed in the animal facilities of the Georgetown University Division of Comparative Medicine. All animal work was done under protocols approved by the Georgetown University Animal Care and Use Committee. Mice were inoculated s.c. into the right posterior flank with 4 × 10⁶ A4573 cells in 100 µL of Matrigel basement membrane matrix (Becton Dickinson). Xenografts were grown to a mean tumor volume of 129 ± 30 mm³. Roscovitine was first dissolved in either absolute methanol or DMSO (1 volume). A carrier solution was produced by using a diluent containing 10% Tween 80, 20% N,N-dimethylacetamide, and 70% polyethylene glycol 400 (Fisher Scientific, Pittsburgh, PA). Mice were randomized into two groups (six animals per group) and treatment was initiated. One group was treated with roscovitine, administered as a single daily i.p. injection, at a dose of 50 mg/kg, for either 5 days or two 5-day series with a 2-day break in between. The control group received i.p. injections of the carrier solution following identical schedules. All mice were sacrificed by asphyxiation with CO₂. Roscovitine-treated mice were euthanized either 7 days after the first injection or up to 4 weeks after completion of the treatment. At those times, tumors were removed, measured, and prepared for TUNEL assays. Primary tumor volumes were calculated by the formula V = (l/2)² × b³, where a is the longest tumor axis and b is the shortest tumor axis. Data are given as mean values ± SE in quantitative experiments. Statistical analysis of differences between groups was done by a one-way ANOVA followed by an unpaired Student’s t test.

**Immunohistochemistry.** All tumors and tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (5 µm) were stained with H&E, assayed for apoptosis by TUNEL as described above, or assessed for expression of cleaved caspase-3, using a rabbit polyclonal anti-cleaved human caspase-3 (Cell Signaling) at 1:50 dilution, and the ABC peroxidase labeling procedure (DakoCytomation California, Inc., Carpinteria, CA) for immunologic detection.

**Results and Discussion**

Treatment of exponentially growing cultures of three EWS (TC-71, SK-ES-1, and A4573) and two PNET (SK-N-MC and TC-32) cell
lines with roscovitine (10 μmol/L) for 24 hours led to a strong inhibition of cell proliferation (above 60%) and the promotion of substantial levels of cell death (>35%) in all cases, relative to cultures incubated with solvent alone (Fig. 1). In contrast, no remarkable effects (<10% inhibition of cell proliferation and apoptotic levels nearly indistinguishable from background) were observed in cultures of similarly treated SK-N-SH neuroblastoma cells (Fig. 1), thus supporting the specificity of the inhibitory action of roscovitine on ESFT cells. Although a previous study reported sensitivity of neuroblastoma cells to roscovitine treatment (29),
it must be pointed out that the inhibitor dose used in that study was 5-fold greater than that used in our experimental protocols.

To further understand the mechanism of roscovitine inhibition of ESFT cell proliferation, we analyzed the cell cycle distribution of the ESFT and neuroblastoma cell lines after treatment with roscovitine (10 \( \mu \text{mol/L} \)) for 24 hours. Relative to untreated controls, results showed a noticeable induction of G1-phase arrest (up to 30%) in TC-71 and SK-N-MC cells, whereas only very slight G1 phase changes were observed for the other ESFT cells and the neuroblastoma SK-N-SH cells (Fig. 2). No significant G2-M arrest was observed in any of the cells tested. Interestingly, the fact that G1 arrest was observed only in TC-71 and SK-N-MC cells correlates with the ability of these cells, but lacking in all the others, to up-regulate the levels of p21\(^{\text{WAF1}}\) protein in response to roscovitine (Fig. 2, left insets). Whether there is any association between this response and the fact that TC-71 and SK-N-MC were the only ones among the cell lines tested that carry a type 1 EWS/FLI-1 translocation (4) remains to be elucidated.

To investigate the possible involvement of cyclin D1 in the observed cell cycle response to roscovitine treatment, cyclin D1 expression levels were examined in roscovitine-treated cells and in untreated controls. Results showed that, contrary to the reduction observed in cell lines derived from other tumor types (17), roscovitine did not cause any remarkable change in cyclin D1 levels in any of the cell lines tested (Fig. 2, right insets). Nevertheless, in agreement with the cell death data shown in Fig. 1, a sizable accumulation of cells in the sub-G1 fraction (around 25%), which is suggestive of apoptotic death, was observed for all ESFT cells, but not for the neuroblastoma SK-N-SH cells (Fig. 2).

Taking into account the sub-G1 information from the fluorescence-activated cell sorting analysis, together with the fact that roscovitine has been reported to induce apoptosis in various cancer cell lines (19, 23–26, 30, 31) and to sensitize cells to radiation (32) and chemotherapy-induced apoptosis (33) both in vitro and in vivo, we did TUNEL assays to explore the possibility that ESFT cells were undergoing apoptosis after roscovitine exposure. Results (Fig. 3) showed that, indeed, roscovitine induced apoptotic cell death in TC-71 and A4573 cells, but not in SK-N-SH cells. Moreover, results from experiments combining TUNEL assays with immunofluorescence using a specific antibody against the cleaved form of human caspase-3 strongly suggested that the apoptotic process induced by roscovitine was caspase-3 dependent (Fig. 3, Cleaved-C3). Quantification of the proportion of cells positive for caspase-3 cleavage (36 \( \pm \) 5.01% for TC-71; 38 \( \pm \) 3.62% for A4573; 3 \( \pm \) 0.8% for SK-N-SH) showed an excellent correlation not only with TUNEL data (Fig. 3), but also with the proportions of dead cells described for each cell line in Fig. 1. The mechanism by which roscovitine induces apoptosis is not well established, although involvement of proapoptotic members of the Bcl-2 family of proteins, such as Bcl-xS, Bax, and Bak, has been suggested (24, 34). Results from Western immunoblot analyses strongly suggested that up-regulation of Bax protein levels is an important event in roscovitine-induced ESFT apoptosis. As shown in Fig. 4A, Bax was markedly up-regulated (by as much as 2.8-fold in TC-32 cells) after roscovitine treatment in each of the three ESFT cell lines tested, whereas Bax levels were actually decreased by \( \sim 50\% \) in SK-N-SH neuroblastoma cells. Furthermore, in agreement with the immunofluorescence data (Fig. 3), cleared caspase-9 (data not

---

**Figure 3.** Roscovitine-induced apoptosis of ESFT cells involves cleavage of caspase-3. ESFT (A4573 and TC-71) cells and neuroblastoma SK-N-SH cells were grown in slide chambers and treated with 10 \( \mu \text{mol/L} \) roscovitine for 16 hours. Then, apoptosis was examined by TUNEL assays (red), caspase-3 cleavage (visualized as green immunofluorescence using a specific antibody to the cleaved caspase-3 polypeptide form), and nuclear morphology (after DAPI staining). Merge of red and green fluorescent signals indicated that caspase-3 cleavage occurred during the apoptotic process induced by roscovitine in the ESFT cells, but not in the neuroblastoma cells.
Figure 4. Roscovitine induces apoptosis in ESFT cells by concomitant up-regulation of the Bax protein and activation of caspase-3. A, ESFT (TC-71, TC-32, A4573) cells and SK-N-SH neuroblastoma cells were treated with 10 μmol/L roscovitine for 24 hours, lysed, and protein levels of surviving, XIAP, Bax, and cleaved caspase-3 were analyzed by Western immunoblot using specific antibodies. Actin was used as the loading control. A representative blot is shown for each protein. Experiments were carried out thrice, with triplicate cultures each time. The relative densitometric intensities of the signals (mean value ± SD) from extracts of control (C) and roscovitine-treated (Rosc) cells are shown under the corresponding bands. B, the apoptotic process induced by treatment of the cells lines indicated with roscovitine (ROSC) was blocked by the simultaneous addition of Ac-DEVD-CHO, a caspase-3/7-specific inhibitor, to the cultures (+Ac-DEVD-CHO columns). The extent of apoptosis inhibition correlated well with the magnitude of the inhibitory effect of Ac-DEVD-CHO on the caspase-3/7 enzymatic activity in the same cells. Cisplatin (CP)-treated cells were used as positive controls for caspase-dependent apoptosis, whereas untreated cells (UT) and cells exposed to solvent alone (DMSO) were used as negative controls. A, A4573; B, TC-71.

shown) and cleaved caspase-3 polypeptides were observed (Fig. 4A) only in extracts of those cells in which the Bax protein was up-regulated by roscovitine, but were undetectable in SK-N-SH cell extracts. In agreement with what was previously observed in other human tumor cell types, such as chronic lymphocytic leukemia (24), the levels of proteins of the IAP family, such as Survivin and XIAP, were significantly down-regulated after roscovitine treatment in all cell lines tested (Fig. 4A). However, the absence of caspase cleavage in SK-N-SH cells strongly suggested that Bax up-regulation is a necessary requisite for the induction of apoptosis by roscovitine.

Furthermore, in agreement with results reported previously on the effect of roscovitine on human B-CLL cells (24), the caspase-3/7 dependence of the apoptotic process induced on ESFT cells by roscovitine was shown by the fact that apoptosis was blocked by treatment with Ac-DEVD-CHO, a caspase-3/7–specific inhibitor. The extent of apoptosis induced by treatment of TC-71 (42.4 ± 0.1%) and A4573 (41.7 ± 2.3%) cultures with roscovitine was markedly reduced when the treatment was carried out in the presence of Ac-DEVD-CHO (Table 1), which essentially prevented the apoptotic action of roscovitine and kept the proportions of apoptotic cells in the cultures at about background levels (Table 1). The decrease in roscovitine-induced apoptotic levels caused by Ac-DEVD-CHO was consistent with the reduction in the apoptotic effect caused in the same cells by cisplatin (Table 1), a known inducer of caspase-dependent apoptosis in ESFT and other cell types (35, 36), and with the extent of inhibition of the caspase-3/7 enzymatic activity induced by the inhibitor in TC-71 and A4573 cells (Fig. 4B). These results showed that the apoptotic process induced by roscovitine in ESFT cells was dependent, at least in part, on caspase-3/7 activation.

Because it has been suggested that roscovitine induces apoptosis by activating the p53 pathway (37), and Bax is a well-known transcriptional target of p53, we analyzed the mRNA levels of Bax after treatment with roscovitine by reverse transcription-PCR. No transcriptional activation of Bax was observed in any of the cells included in this study (data not shown), perhaps as a result of the transcriptional inhibition caused by the reported effect of roscovitine on the loss of RNA polymerase II phosphorylation and total protein levels (17, 25, 38), suggesting that roscovitine treatment causes Bax up-regulation in ESFT cells at the posttranscriptional level by mechanisms involving either posttranslational modification or protein stabilization, such as those described in other experimental systems (39). These results are consistent with the fact that the ESFT cell lines used in this study have mutated or null p53 protein. Additionally, the fact that no up-regulation of Bax mRNA was detected in SN-K-SH cells, which express wild-type p53, suggest that roscovitine did not cause p53 activation in any of the cell lines tested, and that the apoptotic process triggered by roscovitine in ESFT cells is p53 independent. Although the precise molecular mechanism of Bax up-regulation mediated by roscovitine in ESFT cells remains to be elucidated, it seems clear that its overall inhibitory effect on cell proliferation in vitro primarily results from the efficient induction of apoptotic cell death, which in some cases may take place with the concomitant induction of G1 phase cell cycle arrest.

We subsequently investigated the effect of roscovitine in vivo by evaluating the effect of drug treatment on tumor growth using nude mice xenografts of A4573 ESFT cells generated as described under Materials and Methods. When tumors reached a volume of ~130 mm3, animals were injected i.p. with roscovitine or with the carrier solution alone, following different schedules, and tumor growth was measured over a period of up to several weeks. As can be seen in Fig. 5A, tumor growth was significantly slower
values represented a difference of \( f \) already attained a volume treatment initiation, whereas tumors in untreated mice had a mean volume of 130 mm\(^3\). Animals were of A4573 cells in mice were grown to a xenografts established by s.c. inoculation that involves caspase-3 activation.

A,

www.aacrjournals.org 9325 Cancer Res 2005; 65: (20). October 15, 2005

in vivo induction tumor growth delay mediated by the established ESFT xenografts results in Roscovitine treatment of \( f \) grown only 5-day treatment series, tumors in roscovitine-treated animals had a markedly smaller size of individual tumors observed after excision (Fig. 5 A, inset) of tumors excised from \( f \) the time of treatment initiation, whereas tumors in untreated mice had already attained a volume \( \sim 14.5\)-fold their original size. These values represented a difference of \( \sim 11.5\)-fold in tumor volume and, although tumors in roscovitine-treated animals continued to grow very slowly, a significant difference (\( \sim 7.5\)-fold) in tumor size was still evident at the time (day 13; Fig. 5 A) when control animals, whose tumors had grown to \( \sim 15\)-fold their initial size, had to be sacrificed following Institutional Animal Care and Use guidelines. Counting from day 1 of roscovitine treatment, tumors in control animals reached a volume thrice the original in \( \sim 2 \) days, whereas it took \( \sim 10 \) days for the tumors in treated animals to triplicate their initial volume (Fig. 5 A). Overall, this difference indicated that roscovitine treatment resulted in an \( \sim 5\)-fold reduction in tumor growth.

It is important to point out that roscovitine seemed to be particularly effective against ESFT cells, relative to other human tumor cell types, both in culture and in nude mouse xenografts. Our working concentration in culture (10 \( \mu \)mol/L) compares favorably with the reported IC\(_{50}\) values for cytotoxicity of roscovitine on a variety of human tumor and untransformed cell lines (19, 23–26). Furthermore, and most importantly, treatment for 5 consecutive days with only one i.p. injection at 50 mg/kg/d (total roscovitine dose of 250 mg/kg) reduced tumor size, relative to untreated control animals, by \( \sim 85\% \) (days 5-8; Fig. 5 A), whereas treatment schedules including three daily i.p. injections at 100 mg/kg/d for 5 days (total dose of 1,500 mg/kg) were reported to reduce by only 45% and 62%, respectively, the growth of tumors induced in nude mice with human colon (LoVo) and uterine (MESSA-DX5) tumor cell lines (19). The fact that our treatment achieved a better antitumor response with 6-fold lower total doses strongly indicates that roscovitine is substantially more efficient.

![Figure 5. Roscovitine treatment of established ESFT xenografts results in tumor growth delay mediated by the induction in vivo of an apoptotic process that involves caspase-3 activation. A, xenografts established by s.c. inoculation of A4573 cells in mice were grown to a mean volume of 130 mm\(^3\). Animals were randomized into two groups. One group (\( n = 6 \)) was treated with roscovitine, administered as single daily i.p. injections (arrows), at a dose of 50 mg/kg, for either 5 days or two 5-day series with a 2-day break in between. The control group (\( n = 8 \)) received i.p. injections of the carrier solutions following identical schedules. Results shown correspond to one of the experimental replicas using the two 5-day treatment schedule. Tumor growth in roscovitine-treated animals was markedly slower than the growth of tumors in control animals, in agreement with the much smaller size (inset) of tumors excised from individual control or roscovitine-treated animals. Asterisks indicate that the differences observed in tumor growth were statistically significant (\( P = 0.001 \)). B, control and roscovitine-treated mice were euthanized at different times after the first roscovitine injection for up to several weeks after completion of the treatment. At those times, tumors were removed, measured, stained with H&E, and examined for evidence of apoptosis by in situ TUNEL assays and immunohistochemistry with an anti-cleaved caspase-3 specific antibody. Data from the analysis of tumors excised 7 days after the first roscovitine injection are shown. Results indicated that roscovitine efficiently induced apoptosis of ESFT cells in vivo.](#)

### Table 1. Effect of caspase-3/7 inhibition on the apoptotic action of roscovitine on EWS cells

<table>
<thead>
<tr>
<th>Treatment</th>
<th>EWS cell line</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TC-71</td>
</tr>
<tr>
<td></td>
<td>A4573</td>
</tr>
<tr>
<td>UT</td>
<td>7.4 ± 1.2</td>
</tr>
<tr>
<td>DMSO</td>
<td>6.7 ± 3.1</td>
</tr>
<tr>
<td>ROSC</td>
<td>42.4 ± 0.1</td>
</tr>
<tr>
<td>ROSC + Ac-DEVD-CHO</td>
<td>5.8 ± 0.5</td>
</tr>
<tr>
<td>CP</td>
<td>39.9 ± 1.4</td>
</tr>
<tr>
<td>CP + Ac-DEVD-CHO</td>
<td>9.2 ± 3.4</td>
</tr>
</tbody>
</table>

NOTE: Results are given as percentage of apoptotic cells 24 hours after the indicated treatments and correspond to mean ± SD.

Abbreviations: UT, untreated cells; ROSC, roscovitine; CP, cisplatin.
References

Roscovitine Is an Effective Inducer of Apoptosis of Ewing's Sarcoma Family Tumor Cells *In vitro* and *In vivo*

Oscar M. Tirado, Silvia Mateo-Lozano and Vicente Notario